CME/MOC Credit: Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Multidisciplinary Alliances

The immunotherapy revolution has swiftly expanded from advanced lung cancer to the early-stage, resectable, curative-intent setting, and it is radically transforming the standards of care for stage I-III resectable NSCLC. Immunotherapies are now approved in both adjuvant and neoadjuvant settings, and ongoing trials are expected to propel more immunotherapy-based options into early-stage disease settings as well as clarify the best perioperative approaches. What do these developments mean for thoracic surgeons and other members of the multidisciplinary lung cancer care team? How should best practices and standards of care be modernized? What new workflows need to be established to guide individualized treatment selection and make the most of new immunotherapy options to reduce the risk of recurrence and increase the possibility of cure for more patients?

This PeerView Candid Conversations & Clinical Consults educational symposium will bring together top experts to answer these questions. The faculty panel will discuss new, practice-changing evidence, implications and applicability of these advances to practice, and how to best facilitate the incorporation of perioperative immunotherapy into new standards of care to improve outcomes and quality of life for patients with resectable NSCLC.

This CME/MOC activity is provided by PVI, PeerView Institute for Medical Education.

This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and Merck & Co., Inc.

Register for the event at PeerView.com/PeriopLung23-Live